| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka |
NCT05687357: Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma |
|
|
| Recruiting | 2b | 140 | RoW | Tislelizumab, S-1, Oxaliplatin, Nab paclitaxel, Radiation | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Gastric Cancer, Gastroesophageal-junction Cancer | 02/27 | 08/27 | | |
DATE study, jRCTs031190117: Phase II study of durvalumab (MEDI4736) maintenance therapy immediately after completion of chemoradiotherapy for unresectable locally advanced (stage III) non-small cell lung cancer (TORG1937/) |
|
|
| Completed | 2 | 47 | Japan | carboplatin - Generic mfg., cisplatin - Generic mfg., Teysuno (gimeracil/oteracil/tegafur) - Nordic Group, Otsuka, docetaxel - Generic mfg., paclitaxel - Generic mfg., vinorelbine tartrate - Generic mfg., Imfinzi (durvalumab) - AstraZeneca | Nippon Medical School Hospital, AstraZeneca | Untreated locally advanced stage III NSCLC | | | | |
| Active, not recruiting | 2 | 46 | Japan | docetaxel - Generic mfg., oxaliplatin - Generic mfg. | Yakult Honsha Co.,Ltd. | Gastric cancer | | | | |
ChiCTR-TRC-11001439: Establishment of subcutaneous transplantation tumor model and application in adjuvant chemotherapy of gastric cancer |
|
|
| Completed | 2 | 100 | | chemotherapy by the outcome of chemosensitivity assay ;chemotherapy (EOF, DC, XELOX, S-1) | Nantong Tumor Hospital; Shanghai ChemPartner Co., LTD, Shanghai ChemPartner Co., LTD | gastric cancer | | | | |
ChiCTR-IPR-15005923: Phase II clinical study of S-1 and oxaliplatin adjuvant chemotherapy combined with immunotherapy (DC plus CIK) in Locally advanced unresectable or metastatic gastric cancer |
|
|
| Recruiting | 2 | 80 | | chemotherapy ;Chemotherapy combined with immunotherapy | Chinese Academy of Medical Sciences Tumor Hospital; Chinese Academy of Medical Sciences Tumor Hospital, self-finance | gastric cancer | | | | |
ChiCTR-ONC-11001804: Efficacy and Toxicity of Docetaxel with Cisplatin and Oteracil Potassium (S-1) for Advanced Gastric Cancer |
|
|
| Completed | 2 | 59 | | Chemotherapy | The Affiliated Hospital of Guangdong Medical College; The Affiliated Hospital of Guangdong Medical College, Autonomous financing | advanced gastric cancer | | | | |
NCT00227604: S-1 as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 50 | US | tegafur-gimeracil-oteracil potassium | Quintiles | Pancreatic Cancer | | | | |
NCT00227552: S-1 as Second-Line Therapy in Treating Patients With Unresectable or Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 95 | US | tegafur-gimeracil-oteracil potassium | Quintiles | Lung Cancer | | | | |
ChiCTR-TRC-10000873: S-1+CDDP in Patients With Recurrent, Metastatic, or Unresectable Gastric Cancer |
|
|
| Completed | 2 | 270 | | S-1 80mg/m2/d orally taken twice daily D1-21; CDDP 20mg/m2 infusion D1-4 ;5-FU 800mg/m2/24h infusion D1-5; CDDP 20mg/m2 infusion D1-4 | Shenzhen Main Luck Pharmaceuticals Inc.; Proswell Medical Company, Shenzhen Main Luck Pharmaceuticals Inc. | Recurrent, metastatic or unresectable gastric cancer | | | | |
JCOG0805, UMIN000001685: Japanese A Randomized Phase II Study of Gemcitabine + S-1 Combination Versus S-1 Monotherapy in Advanced Biliary Tract Cancer |
|
|
| Completed | 2 | 100 | Japan | gemcitabine - Generic mfg. | Japan Clinical Oncology Group (JCOG), Japanese Ministry of Health, Labour and Welfare | Advanced biliary tract cancer | | | | |
NCT00227578: S-1 and Cisplatin as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery |
|
|
| Active, not recruiting | 2 | 60 | US | cisplatin, tegafur-gimeracil-oteracil potassium | Quintiles | Lung Cancer | | | | |
ChiCTR-TNC-10000929: A phase II trial of S-1 and concurrent radiotherapy + S-1 chemotherapy for locally advanced pancreatic cancer |
|
|
| Completed | 2 | 30 | | of S-1 and concurrent radiotherapy + S-1 chemotherapy | Zhongshan Hospital, Fudan University; Level of the institution：, Zhongshan Hospital Fudan University | pancreatic cancer | | | | |
| Completed | 2 | 60 | | different drug ;S1 capsule | Shanghai Changhai Hospital; Level of the institution：, funding from the company | rectal cancer | | | | |
2014-000394-39: Full dose S1 compared to reduced dose S-1/oxaliplatin. First-line treatment for older patients with metastic colorectal cancer. S1 eller S1/oxaliplatin som 1. linje behandling til ældre patienter med metastaserende kolerektalcancer. |
|
|
| Ongoing | 2 | 160 | Europe | oxaliplatin, irinotecan, Avastin, S1, 23388, Concentrate and solvent for solution for injection/infusion, Concentrate and solvent for solution for infusion, Capsule, hard, Oxaliplatin, Irinotecan, Avastin, Teysuno | Odense University Hospital, Odense University Hospital | Treatment of older (≥ 70 years) patients with metastatic colorectal cancer, Colorectal cancer, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-TNC-11001362: A phase II trial of S-1 and concurrent radiotherapy plus S-1 chemotherapy for peri-ampullar carcinoma after radical excision |
|
|
| Recruiting | 2 | 50 | | S-1 and concurrent radiotherapy + S-1 chemotherapy | Zhongshan Hospital Fudan University; Zhongshan Hospital Fudan University, Zhongshan Hospital Fudan University | peri-ampullar carcinoma | | | | |
ChiCTR-OPC-15005892: Phase II Clinical Trial of Oxaliplatin in Combination with S-1 in the Treatment of Advanced primary liver cancer |
|
|
| Recruiting | 2 | 200 | | Oxaliplatin + S-1 | Affiliated Cancer Hospital of Guangxi Medical University/Cancer Hospital of Guangxi Zhuang Autonomous Region; Affiliated Cancer Hospital of Guangxi Medical University, Guangxi nature science fund; Guangxi health care key scientific research project; Guangxi self-financing scientific research project | advanced primary liver cancer | | | | |
SRIT-LC study, ChiCTR-OIN-16008205: S-1 for elderly patients with locally advanced squamous cell carcinoma of the lung radiation sensitizing Observation of the clinical efficacy and safety study |
|
|
| Recruiting | 2 | 30 | | Concurrent radiotherapy with S1 regimen | Heilongjiang Land Reclamation Bureau General Hospital; Heilongjiang Land Reclamation Bureau General Hospital, NA | squamous cell carcinoma of the lung | | | | |
HiSCO-02, UMIN000004976: A Multicenter Phase II trial of TS-1/oxaliplatin (SOX) +bevacizumab in patients with unresectable advanced/metastatic colorectal cancer |
|
|
| Completed | 2 | 55 | Japan | oxaliplatin - Generic mfg., Avastin (bevacizumab) - Roche | Hiroshima Prefectural Hospital | Unresectable advanced/metastatic colorectal cancer | | | | |
NCT03428425: A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells |
|
|
| Not yet recruiting | 2 | 38 | NA | paclitaxel apatinib S-1 | Hebei Medical University | Gastric Cancer | 12/18 | 01/24 | | |
ChiCTR-IIR-17010609: Randomized, open, controlled phase II clinical study of apatinib piece (AiTan) combined the Sox scheme first-line treatment of advanced gastric cancer under the background of panoramic cancer gene detection. |
|
|
| Recruiting | 2 | 70 | | Apatinib Mesylate Tablets 250mg, Oxaliplatin 130mg/m2, Tegafur,Gimeracil and Oteracil Porassium Capsules 80mg/m2/d, 14 days ;Oxaliplatin 130mg/m2, Tegafur,Gimeracil and Oteracil Porassium Capsules 80mg/m2/d, 14 days | Jiangsu Provincial People's Hospital; Jiangsu Provincial People's Hospital, Hengrui pharmaceutical co., LTD. Offers for researchers and funding | A gleam of gastric cancer | | | | |
ChiCTR-OIH-17012822: The prospective, single-arm, single-center, exploratory clinical study of Apatinib combined with Tegafur Gimeracil Oteracil Potassium Capsule in treating patients with Advanced esophageal squamous carcinoma |
|
|
| Recruiting | 2 | 34 | | Apatinib combined with Tegafur Gimeracil Oteracil Potassium Capsule | Shanxi Provincial Tumour Hospital; Shanxi Provincial Cancer Hospital, Chinese Anti-Cancer Association- HengRui pharmaceutical innovative medicine clinical research fund | esophagus cancer | | | | |
ChiCTR1900020485: Phase II study for bevacizumab combined with S-1 and raltitrexed in the treatment of metastatic colorectal cancer resistant to 5-fluorouracil / oxaliplatin /irinotecan |
|
|
| Recruiting | 2 | 43 | | bevacizumab combined with S-1 and raltitrexed | West China Hospital of Sichuan University; West China Hospital, Sichuan University, researchers | metastatic colorectal cancer | | | | |
IMPACT-RC, UMIN000011457: Phase II trial of induction mFOLFOX6 plus Avastin followed by neoaduvant chemoradiotherapy with TS-1 for MRI-defined high-risk rectal cancer |
|
|
| Completed | 2 | | Japan | Avastin (bevacizumab) - Roche, 5-fluorouracil - Generic mfg., oxaliplatin - Generic mfg., leucovorin calcium - Generic mfg. | The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Takeda Science Foundation;Sumitomo Mitsui Banking Corporation;Japanese Foundation for Multidisciplinary Treatment of Cancer | Resectable locally advanced rectal cancer | | | | |
2017-004675-31: Randomised study for second line treatment with nal-IRI and S1 in pancreatic cancer. 2e lijns studie met nal-IRI en S1 voor patiënten met alvleesklierkanker |
|
|
| Not yet recruiting | 2 | 120 | Europe | onivyde, teysuno, 5 fluorouracil, EMA/515476/2016, EMA/20503/2012, EMA/706456, Powder for solution for injection/infusion, Capsule, Solution for infusion, ONIVYDE, Teysuno, fluorouracil | Academic Medical Center, ACADEMIC MEDICAL CENTRE AMSTERDAM, University of Amsterdam | pancreatic cancer pancreas kanker, pancreatic cancer alvleesklier kanker, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-OIC-17011385: The clinical research of Mesylate apatinib combined with docetaxel and S-1 as the first-line treatment of metastatic gastric cancer |
|
|
| Recruiting | 2 | 48 | | First-line treatment | Zhongnan Hospital of Wuhan University; Zhongnan Hospital, Innovative funds in the hospital | Advanced Gastric Cancer | | | | |
ChiCTR-OIC-17012124: Apatinib combined with metronomic S-1 as first-line treatment in patients with advanced primary liver cancer: a multi-center, single-arm, prospective, open-label phase II clinical trial |
|
|
| Recruiting | 2 | 100 | | Apatinib 500mg orally, qd, d1-28, with 28 days as a cycle; S-1, 20mg orally, bid, d1-28, with 28 days as a cycle; Both drugs take until the disease progression or untolerable toxicities occurred | The Affiliated Tumor Hospital of Guangxi Medical University; The Affiliated Tumor Hospital of Guangxi Medical University, self-financing | primary carcinoma of liver | | | | |
ChiCTR2200056029: Efficacy and safety of intravenous and intraperitoneal paclitaxel plus oral S-1 in gastric cancer patients with peritoneal metastasis |
|
|
| Completed | 2 | 67 | | Intravenous and intraperitoneal paclitaxel plus oral S-1 | Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Self-financing | Gastric cancer | | | | |
ASMA-GC, ChiCTR1800019382: An ambispective cohort study for apatinib versus S-1 maintenance treatment after first-line chemotherapy in advanced gastric cancer |
|
|
| Recruiting | 2 | 80 | | Blank control ;S-1 ;Apatinib | Shandong Cancer Hospital; Shandong Cancer Hospital, Jiangsu hengrui pharmaceutical co., LTD | Advanced gastric cancer | | | | |
NCT03154983: The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer |
|
|
| Recruiting | 2 | 48 | RoW | docetaxel, Tegafur, Mesylate Apatinib | Zhou Fuxiang, Hubei Cancer Hospital, Huangshi Central Hospital, China, The Central Hospital of Huanggang, Xianning Central Hospital, Shiyan Taihe Hospital, The first hospital of Zaoyang, Hanchuan City people's Hospital, Yangxin People's Hospital, Tianmen People's Hospital | Metastatic Gastric Cancer | 12/20 | 12/21 | | |
NCT06250894: Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction |
|
|
| Recruiting | 2 | 32 | RoW | PD-1inhibitor | Wuhan Union Hospital, China | PD-1, Neoadjuvant Chemoradiotherapy, Gastroesophageal Junction Cancer | 06/24 | 03/25 | | |
ChiCTR1800014367: The efficacy and saftey of Avastin plus S-1 compared with Docetaxel in the second line treatment of advanced lung adenocarcinoma with negtive driven gene |
|
|
| Not yet recruiting | 2 | 128 | | Avastin ;Docetaxel | Yin Yi; Level of the institution：, Qihang funding of Fujian medical university | lung cancer | | | | |
ABXS301, ChiCTR1800016899: Phase 2 Trial of preoperative treatment with Nab-paclitaxel Plus S-1 in Patients With borderline resectable Pancreatic Cancer |
|
|
| Recruiting | 2 | 50 | | nab-paclitaxel plus S-1 as neoadjuvant therapy | Department of Hepato-pancreato-biliary surgical oncology, Chinese PLA General Hospital; Chinese PLA General Hospital, self-raised funds | pancreatic cancer | | | | |
ChiCTR1900022946: A phase II study for Tegafur, Gimeracil and Oteracil potassium with or without Thalidomide for heavily treated colorectal cancer patients |
|
|
| Not yet recruiting | 2 | 100 | | Tegafur combined with Thalidomide ;Tegafur | First Affilliated Hospital of Xi'an Jiaotong University; First Affilliated Hospital of Xi'an Jiaotong University, Funding from the first affiliated hospital of Xi'an Jiaotong University | colorectal cancer | | | | |
NCT04207918: A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer |
|
|
| Completed | 2 | 55 | RoW | Radiotherapy, Nimotuzumab, S-1 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Chemoradiotherapy, Nimotuzumab, Unresectable Malignant Neoplasm | 12/22 | 06/23 | | |
NCT03946969: Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer |
|
|
| Active, not recruiting | 2 | 30 | RoW | Sintilimab, IBI308, Liposomal Paclitaxel + Cisplatin + S-1, PFC | The First Affiliated Hospital with Nanjing Medical University, Innovent Biologics (Suzhou) Co. Ltd. | Esophageal Squamous Cell Carcinoma | 11/21 | 10/22 | | |
NCT04694404: Efficacy and Safety of S-1 Plus Oxaliplatin in First-line Treatment of Ederly Patients With Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 60 | RoW | S-1,Oxaliplatin | Aiping Zhou | S-1 Plus Oxaliplatin | 12/21 | 12/22 | | |
NCT04571489: A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer |
|
|
| Not yet recruiting | 2 | 60 | RoW | Gimatecan, ST1481, tegafur, gimeracil and oteracil potassium, gemcitabine | Lee's Pharmaceutical Limited | Pancreatic Cancer | 12/21 | 12/23 | | |
NCT03814759: Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 102 | RoW | TS-1 + cisplatin, radiation | Yonsei University | Gastric Adenocarcinoma | 12/21 | 07/22 | | |
ChiCTR1900020520: Randomized Controlled Trial for EGFR-TKIs Plus S-1 or EGFR-TKIs as the First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations. |
|
|
| Recruiting | 2 | 80 | | EGFR-TKIs plus S-1 ;EGFR-TKIs | Liuzhou General Hospital; Liuzhou General Hospital, Beijing Xisike Clinical Oncology Research Foundation | Lung Cancer | | | | |
ChiCTR1900020876: Phase 2 clinical study for the precise 3DCRT/IMRT technology combined with S-1 in the treatment of elderly patients with locally advanced esophageal squamous cell carcinoma |
|
|
| Not yet recruiting | 2 | 150 | | 3DCRT/IMRT technology combined with S-1 | Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, Jiangsu youth medical talent project | Esophagus squamous cell carcinoma | | | | |
NCT04890392: Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC |
|
|
| Recruiting | 2 | 20 | RoW | PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin) | Wuhan Union Hospital, China | Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma | 01/22 | 02/22 | | |
ZLK-XXY-1, NCT04202484: Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 20 | NA | Toripalimab combined with oxaliplatin and Tegafur,Gimeracil and Oteracil Porassium Capsules | RenJi Hospital | Gastric Cancer | 02/22 | 02/23 | | |
NCT04152889: A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer |
|
|
| Recruiting | 2 | 20 | RoW | Camrelizumab, SHR-1210, S-1, Docetaxel | RenJi Hospital | Gastric Cancer Stage III | 04/22 | 12/22 | | |
ChiCTR1900021069: A prospective, open, randomized controlled trial for evaluating the safety and efficacy of oral capecitabine plus local radiotherapy for elderly patients with esophageal squamous cell carcinoma |
|
|
| Not yet recruiting | 2 | 34 | | Capecitabine ;S-1 | Chinese PLA General Hospital; Chinese PLA General Hospital, self-financing | elderly esophageal cancer | | | | |
NCT04377048: Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer |
|
|
| Not yet recruiting | 2 | 38 | NA | Nivolumab, Gemcitabine, Tegafur-Gimeracil-Oteracil, S-1 | National Taiwan University Hospital, Ono Pharmaceutical Co. Ltd, ACT Genomics, TTY Biopharm | Stage IV Pancreatic Cancer | 07/22 | 12/22 | | |
NCT04195828: Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer |
|
|
| Active, not recruiting | 2 | 53 | RoW | Camrelizumab, Apatinib Mesylate, nab-paclitaxel, S1 | Fujian Medical University | Advanced Gastric Cancer | 07/22 | 03/25 | | |
NCT04062058: A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 82 | RoW | SIB-IMRT, S-1, SOX, Surgery | Jing Jin, M.D., Beijing Hope Run | Gastric Cancer, Neoadjuvant Therapy | 09/22 | 09/23 | | |
NCT04694183: The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer |
|
|
| Completed | 2 | 37 | RoW | Camrelizumab, SHR-1210, S-1, Tegafur Gimeracil Oteracil Potassium Capsule, Oxaliplatin, Paclitaxel | Quan Wang | Stomach Neoplasms | 05/23 | 05/23 | | |
NCT03904225: Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis |
|
|
| Recruiting | 2 | 220 | RoW | Tegafur-Gimeracil-Oteracil | Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 12/22 | 12/22 | | |
NCT03519074: Cisplatin Combined with Oral TS-1 in Patients with Advanced Solid Tumors with Different Degrees of Liver Dysfunction |
|
|
| Active, not recruiting | 2 | 48 | RoW | TS-1 combined with cisplatin | National University Hospital, Singapore | Cancer, Liver Dysfunction | 09/24 | 12/25 | | |
NCT04856761: A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection |
|
|
| Recruiting | 2 | 160 | RoW | S-1, Tegafur, Capecitabine, XELODA | Fudan University | Biliary Tract Neoplasms, Recurrence, Cholangiocarcinoma, Gall Bladder Cancer | 12/22 | 12/24 | | |
ChiCTR-ONC-13003060: Phase II study of adjuvant S-1 concurrent radiotherapy in pancreatic cancer patients with high risk factors |
|
|
| Recruiting | 2 | 140 | | external beam radiotherapy ;chemotherapy with S-1 | Zhongshang Hospital, Fudan University; Zhongshang Hospital, Fudan University, Zhongshan, Fudan University | Pancreatic Cancer | | | | |
NCT04258657: Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer |
|
|
| Not yet recruiting | 2 | 20 | RoW | paclitaxel-albumin and S-1 | Beijing Friendship Hospital | Gastric Cancer | 12/22 | 12/22 | | |
ChiCTR2100041825: Objective to evaluate the feasibility of karelizumab injection combined with dual drug chemotherapy (tegafur / albumin paclitaxel) and / or apatinib in the treatment of advanced unresectable gastric cancer |
|
|
| Recruiting | 2 | 30 | | carrelizumab injection combined with dual chemotherapy (S-1/albumin paclitaxel) and/or apatinib | The First Affiliated Hospital of PLA Air Force Medical University; Department of Gastroenterology, First Affiliated Hospital of PLA Air Force Military Medical University, N/A | Advanced unresectable gastric cancer | | | | |
NCT04808687: Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer |
|
|
| Recruiting | 2 | 72 | RoW | Nab paclitaxel and S-1 | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Neoplasms | 02/23 | 02/24 | | |
NCT06427005: Fruquintinib Plus S-1 and Raltitrexed (RSF) for mCRC |
|
|
| Recruiting | 2 | 66 | RoW | Fruquintinib, Elunate, S-1, Tegafur,Gimeracil and Oteracil Potassium Capsules, raltitrexed, thymidylate synthase inhibitor | West China Hospital | Fruquintinib, S-1, Raltitrexed | 06/24 | 12/24 | | |
NCT04258644: Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer |
|
|
| Not yet recruiting | 2 | 30 | RoW | Camrelizumab+Apatinib+Paclitaxel-albumin+S-1 | Beijing Friendship Hospital | Gastric Cancer | 02/23 | 02/23 | | |
NCT04221555: Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 68 | RoW | Docetaxel, Oxaliplatin, S-1 and Durvalumab, Durvalumab and Tremelimumab | Asan Medical Center | Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | 04/25 | 04/25 | | |
| Recruiting | 2 | 53 | RoW | Tislelizumab, Oxaliplatin, S-1, Capecitabine | Sun Yat-sen University | Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach | 11/24 | 11/27 | | |
NCT05138159: A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen |
|
|
| Not yet recruiting | 2 | 10 | RoW | Donafenib, S1 | Fudan University | Metastatic Pancreatic Cancer | 05/23 | 07/23 | | |
NCT03815461: Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer |
|
|
| Not yet recruiting | 2 | 60 | RoW | Nab-paclitaxel and S-1 | Chinese Academy of Medical Sciences | Locally Advanced Pancreatic Cancer | 06/23 | 10/23 | | |
NCT04319471: Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 70 | RoW | Capecitabine/S-1, Maintenance chemotherapy, Chemotherapy, Head and neck radiotherapy, Local Consolidative Therapy | Fujian Cancer Hospital, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 06/23 | 06/23 | | |
NCT05346874: Neoadjuvant TACiE in Locally Advanced Gastric Cancer |
|
|
| Not yet recruiting | 2 | 37 | RoW | Oxaliplatin, Teysuno, Transarterial chemoembolization (TACE) | Shanghai Zhongshan Hospital | Gastric Cancer | 06/23 | 05/25 | | |
NCT05441254: Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study |
|
|
| Not yet recruiting | 2 | 33 | NA | Camrelizumab; Nab-paclitaxel; S-1, Arm PD-1 | Zhongshan Hospital Xiamen University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Stage IV Gastric Cancer With Metastasis | 06/23 | 12/23 | | |
PERSIST, NCT04982939: Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 210 | RoW | Sintilimab, IBI308, S-1, Oxaliplatin | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer, Perioperative, Sintilimab | 06/23 | 06/24 | | |
NCT05184803: A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer |
|
|
| Recruiting | 2 | 63 | RoW | Docetaxel injection, oxaliplatin, S-1 | Asan Medical Center | Stomach Neoplasm | 06/25 | 12/25 | | |
NCT05410847: Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells |
|
|
| Not yet recruiting | 2 | 30 | NA | Camrelizumab Nab-Paclitaxel S-1 | Hebei Medical University | Gastric Cancer | 06/23 | 06/25 | | |
ChiCTR2100048252: A single-center, prospective, randomized controlled clinical study of nab-paclitaxel combined with oxaliplatin and S-1 (S-1) regimen and docetaxel combined with oxaliplatin and S-1 (s-1) regimen for neoadjuvant treatment of locally advanced gastric cancer |
|
|
| Not yet recruiting | 2 | | | Nab-paclitaxel combined with oxaliplatin and S-1 ;Docetaxel in combination with oxaliplatin and S-1 | Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai Shenkang's three-year action plan for ''promoting clinical skills and clinical innovation in municipal hospitals'' | Gastric cancer | | | | |
NCT05048524: Peri-operative SLOG for Localized Pancreatic Cancer |
|
|
| Recruiting | 2 | 64 | RoW | S-1, leucovorin, oxaliplatin and gemcitabine | National Health Research Institutes, Taiwan | Pancreatic Ductal Adenocarcinoma, Pancreas Cancer | 08/24 | 08/25 | | |
NCT05519202: Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer |
|
|
| Not yet recruiting | 2 | 47 | NA | S-1,Oxaliplatin, Penpulimab, SOX and Penpulimab | The Central Hospital of Lishui City | Gastric Cancer | 08/23 | 08/24 | | |
| Active, not recruiting | 2 | 52 | RoW | Camrelizumab, SHR-1210, Oxaliplatin, Tegafur gimeracil oteracil potassium capsule | Yu jiren | Gastric Cancer Stage III | 12/23 | 03/26 | | |
NCT05529355: Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 45 | NA | Envafolimab plus Endostar and S-1, Envafolimab combined with Recombinant Human Endostatin Injection/Tegafur,Gimeracil and Oteracil Porassium Capsules, Envafolimab plus Endostar, Envafolimab combined with Recombinant Human Endostatin Injection, Envafolimab plus S-1, Envafolimab combined with Tegafur,Gimeracil and Oteracil Porassium Capsules | Anhui Chest Hospital | Carcinoma, Non-Small-Cell Lung | 09/23 | 09/23 | | |
NeoRacing, NCT05161572: Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 152 | RoW | Oxaliplatin, Tegafur-Gimeracil-Oteracil, Sintilimab, Concurrent chemoradiation, D2/R0 gastrectomy | Fudan University | Stomach Neoplasms, Esophagogastric Junction Disorder, Neoadjuvant Therapy, Chemoradiotherapy, Immunotherapy, Gastrectomy, Adenocarcinoma, Adjuvant Therapy | 09/23 | 09/26 | | |
NCT05095467: HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction |
|
|
| Not yet recruiting | 2 | 157 | NA | HIPEC, Paclitaxel injection, Paclitaxel-albumin, Tegafur-gimeracil-oteracil potassium, Surgery+HIPEC | Xuefei.Wang | Stomach Neoplasms, Peritoneal Metastases | 10/23 | 10/26 | | |
NCT04863430: Apatinib With Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma Of The Stomach |
|
|
| Recruiting | 2 | 41 | RoW | Apatinib, Apatinib Mesylate Tablets, Oxaliplatin, Oxaliplatin for Injection, S1, Tegafur Gimeracil Oteracil Potassium Capsule | Peking University | Gastric Cancer | 12/23 | 12/25 | | |
NCT05204173: Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis |
|
|
| Recruiting | 2 | 30 | RoW | sintilimab, paclitaxel and S-1 | Ruijin Hospital | Gastric Cancer Stage IV, Peritoneal Metastases | 12/23 | 12/23 | | |
NCT06256328: A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) |
|
|
| Active, not recruiting | 2 | 210 | Japan, RoW | ONO-4578, Oxaliplatin, Capecitabine, S-1, Tegafur-gimeracil-oteracil potassium, Nivolumab, Opdivo, Placebo | Ono Pharmaceutical Co. Ltd | Gastric Cancer | 11/25 | 07/27 | | |
NICE, NCT04744649: Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial |
|
|
| Recruiting | 2 | 110 | RoW | XELOX or SOX, Control group, JS001+XELOX or SOX, Experimental group and Exploratory group | Nanfang Hospital of Southern Medical University, Shanghai Junshi Bioscience Co., Ltd. | Gastric Cancer, Stomach Neoplasm | 12/23 | 12/24 | | |
NCT03406299: Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 92 | RoW | Tegafur, S-1, Leucovorin, Folinic acid, Oxaliplatin, oxalic, Gemcitabine, Gemmis, Cisplatin | National Health Research Institutes, Taiwan | Biliary Tract Neoplasms | 12/24 | 12/24 | | |
ChiCTR1800017583: S-1 adjuvant chemotherapy vs watchful waiting in patients with high-risk locoregionally advanced nasopharyngeal carcinoma: a prospective, randomized, controlled, open-label phase II trial |
|
|
| Recruiting | 2 | 256 | | S-1 adjuvant chemotherapy ;watchful waiting | Affiliated Cancer Hospital and institution of Guangzhou Medical University; Affiliated Cancer Hospital and institution of Guangzhou Medical University, Self-raised | nasopharyngeal carcinoma | | | | |
| Recruiting | 2 | 150 | RoW | Neoadjuvant gemcitabine plus nab-paclitaxel, Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT, Neoadjuvant S-1 plus nab-paclitaxel with SBRT | Changhai Hospital | Pancreatic Cancer | 12/23 | 12/23 | | |
NCT03403101: The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer |
|
|
| Recruiting | 2 | 65 | RoW | S1, Oxaliplatin, Irinotecan | Fudan University | Carcinoma, Pancreatic Ductal | 12/23 | 07/24 | | |
NCT04675866: Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 46 | RoW | Camrelizumab, Albumin-bound paclitaxel, S-1 | Henan Cancer Hospital | Advanced Gastric Adenocarcinoma | 12/23 | 12/23 | | |
NCT05052931: Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 10 | RoW | Nab-paclitaxel combined with oxaliplatin and S-1 | Jianjun Yang, CSPC Ouyi Pharmaceutical Co., Ltd. | Gastric Cancer | 12/23 | 12/23 | | |
NCT05111444: Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 65 | RoW | Camrelizumab, Pyrotinib, Capecitabine, Oxaliplatin, Paclitaxel, S-1 | Fudan University | Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma | 12/23 | 06/24 | | |
NCT04782791: Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer |
|
|
| Not yet recruiting | 2 | 30 | NA | Nivolumab plus SOX, Nivo + SOX, Nivolumab, Nivo, Gastrectomy | Chinese PLA General Hospital | Gastric Cancer, Chemotherapy Effect | 12/23 | 05/24 | | |
NCT06166589: Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer |
|
|
| Not yet recruiting | 2 | 19 | RoW | Zimberelimab, Oxaliplatin, S-1, Irinotecan | Shanghai Zhongshan Hospital | Previously AG Chemotherapy Treated Pancreatic Cancer | 01/26 | 01/27 | | |
NCT06213519: HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis |
|
|
| Not yet recruiting | 2 | 69 | NA | S-1, Oxaliplatin sintilimab HIPEC | Sichuan University | Peritoneal Metastases, Gastric Cancer | 05/27 | 06/27 | | |
NCT06046963: Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites |
|
|
| Recruiting | 2 | 35 | RoW | Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion, Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected | Zhejiang Cancer Hospital | Gastric Cancer, Peritoneal Metastases, Ascites, Malignant | 03/24 | 03/25 | | |
| Recruiting | 2 | 140 | RoW | S-1, Tegafur,Gimeracil and Oteracil Potassium Capsules, Toripalimab, Toripalimab Injection, Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Nanfang Hospital, Southern Medical University, Zhujiang Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University, Xiangya Hospital of Central South University, Wuhan University | Locally Advanced Esophageal Squamous Cell Carcinoma | 12/26 | 12/28 | | |
NCT06487715: Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis |
|
|
| Enrolling by invitation | 2 | 42 | RoW | albumin-bound paclitaxel (260 mg/m2, d1), S-1, sintilimab, bevacizumab | Wuhan Union Hospital, China | Gastric Cancer Peritoneal Metastases | 03/25 | 03/26 | | |
NCT05636150: A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 48 | RoW | Fruquintinib in Combination with S-1 | Peking Union Medical College Hospital | Esophageal Squamous Cell Carcinoma | 03/24 | 08/24 | | |
NCT06238167: Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC |
|
|
| Not yet recruiting | 2 | 40 | NA | Tislelizumab, S-1 therapy, low dose SOX therapy | First Affiliated Hospital of Wenzhou Medical University | Gastric Cancer | 12/26 | 12/28 | | |
NCT06341595: Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM |
|
|
| Recruiting | 2 | 40 | RoW | Sintilimab, Extraperitoneal radiation therapy, Oxaliplatin, S-1 | The First Affiliated Hospital with Nanjing Medical University | Gastric Cancer, Gastric Cancer Metastatic to Regional Lymph Nodes | 12/25 | 12/26 | | |
NCT06383078: HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer |
|
|
| Not yet recruiting | 2 | 120 | NA | HR070803, Irinotecan Liposome, Oxaliplatin, L-OHP, Tegafur, S-1, Folinic acid, LV, 5-Fluorouracil, 5-FU | The First Affiliated Hospital with Nanjing Medical University | Efficacy and Safety | 03/27 | 12/27 | | |
ChiCTR2100052478: Exploratory clinical study of cindilimab combined with S-1 oral plus paclitaxel injection intravenous and intraperitoneal infusion chemotherapy in the treatment of peritoneal metastasis and transformation of gastric cancer |
|
|
| Recruiting | 2 | 40 | | Paclitaxel injection intraperitoneal perfusion plus intravenous chemotherapy + S-1 oral + Intravenous infusion of cindilimab injection | Affiliated Cancer Hospital of Shandong First Medical University; Cancer Hospital Affiliated to Shandong First Medical University, No | gastric cancer | | | | |
NCT06385873: RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer |
|
|
| Not yet recruiting | 2 | 32 | NA | RC48, Disitamab Vedotin, Adebrelimab, Apatinib, S-1, S-1tegafur, gimeracil and oteracil potassium | The First Affiliated Hospital with Nanjing Medical University | Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | 05/27 | 05/28 | | |
Stars, NCT06422858: Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 37 | RoW | Serplulimab, Tegafur-gimeracil-oteracil potassium capsule(S1), Radiotherapy, Cisplatin | Zhejiang Cancer Hospital | Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma | 04/25 | 04/26 | | |
NCT06255379: Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 52 | RoW | Fuquinitinib+Tegafur Gimeracil Oteracil | Guangzhou University of Traditional Chinese Medicine | Metastasis Colorectal Cancer, Colon Cancer, Rectal Cancer | 03/27 | 03/27 | | |
PPIO-008, NCT06354140: Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY |
|
|
| Recruiting | 2 | 45 | RoW | Tegafur, tislelizumab | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Esophageal Squamous Cell Carcinoma | 05/27 | 05/28 | | |
